Reading CGEM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CGEM free→Reading CGEM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CGEM free→QuarterlyIQ Insights · CGEM
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. CLN-978 On June 10, 2026, the Company shared updated clinical data from its Phase 1 OUTRACE clinical trials for CLN-978 in patients with treatment-refractory RA (“OUTRACE RA”) and in patients with treatment-refractory moderate to severe SLE (“OUTRACE SLE”). As of May 20, 2026, new multi-dose data in the Phase 1 OUTRACE RA clinical trial demonstrate the robust efficacy profile of CLN-978 observed in two heavily pre-treated, poly-refractory patients, including a DAS28-ESR remissio…
Other Events. On June 6, 2026, the Company shared initial clinical data from its Phase 1 OUTRACE clinical trials for CLN-978 in patients with treatment-refractory RA ("OUTRACE RA") and in patients with treatment-refractory moderate to severe SLE ("OUTRACE SLE"). As of May 15, 2026, 29 patients had been evaluated across various dose levels in the OUTRACE SLE and RA clinical trials. SLE (n=18) RA (n=11) Dose levels investigated Safety PD* Efficacy Safety PD* Efficacy Cohort 1 (D1: 10 μg) 3 3 3…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.